August 2025
1. MAJIDI A, Rinaldi S, Biessy C, Vozar B, et al
   Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study.
   J Natl Cancer Inst. 2025 Aug 14:djaf222. doi: 10.1093.
   

   >> Share

   
   
2. JONES RR, Madrigal JM, Medgyesi DN, Fisher JA, et al
   Serum concentrations of per- and polyfluoroalkyl substances and risk of ovarian cancer.
   J Natl Cancer Inst. 2025 Aug 1:djaf204. doi: 10.1093.
   

   >> Share

   
   April 2025
3. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
   Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
   J Natl Cancer Inst. 2025;117:728-736.
   

   >> Share

   
   
4. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
   High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
   J Natl Cancer Inst. 2025;117:719-727.
   

   >> Share

   
   February 2025
5. LEHRER S
   Re: Timing of depression in relation to risk of ovarian cancer.
   J Natl Cancer Inst. 2025 Feb 25:djaf043. doi: 10.1093.
   

   >> Share

   
   January 2025
6. ROBERTS AL, Townsend MK, Chibnik LB, Kubzansky LD, et al
   Timing of depression in relation to risk of ovarian cancer.
   J Natl Cancer Inst. 2025 Jan 2:djae348. doi: 10.1093.
   

   >> Share

   
   December 2024
7. EVANS DG, Flaum N, Crosbie EJ
   High-grade serous ovarian cancer after bilateral salpingo-oophorectomy.
   J Natl Cancer Inst. 2024 Dec 31:djae328. doi: 10.1093.
   

   >> Share

   
   
8. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
   Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
   J Natl Cancer Inst. 2024;116:1904-1913.
   

   >> Share

   
   November 2024
9. NAROD SA, Gronwald J, Karlan B, Moller P, et al
   Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers.
   J Natl Cancer Inst. 2024;116:1753-1760.
   

   >> Share

   
   October 2024
10. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    

    >> Share

    
    August 2024
11. FOULKES WD, Polak P
    Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer.
    J Natl Cancer Inst. 2024 Aug 22:djae184. doi: 10.1093.
    

    >> Share

    
    
12. MYERS ER
    Reducing ovarian cancer mortality through screening: an impossible dream?
    J Natl Cancer Inst. 2024 Aug 12:djae175. doi: 10.1093.
    

    >> Share

    
    
13. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    

    >> Share

    
    July 2024
14. ISHIZAWA S, Niu J, Tammemagi MC, Irajizad E, et al
    Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework.
    J Natl Cancer Inst. 2024 Jul 23:djae145. doi: 10.1093.
    

    >> Share

    
    
15. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
    Ovarian cancer risk factors in relation to family history.
    J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
    

    >> Share

    
    June 2024
16. BAKER SG, Etzioni R
    Prediagnostic evaluation of multicancer detection tests: design and analysis considerations.
    J Natl Cancer Inst. 2024;116:795-799.
    

    >> Share

    
    May 2024
17. DAVIS EW, Attwood K, Prunier J, Paragh G, et al
    The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.
    J Natl Cancer Inst. 2024 May 28:djae112. doi: 10.1093.
    

    >> Share

    
    February 2024
18. CAO A, Esserman DA, Cartmel B, Irwin ML, et al
    Association between diet quality and ovarian cancer risk and survival.
    J Natl Cancer Inst. 2024 Feb 23:djae040. doi: 10.1093.
    

    >> Share

    
    July 2023
19. PHUNG MT, Lee AW, McLean K, Anton-Culver H, et al
    A framework for assessing interactions for risk stratification models: the example of ovarian cancer.
    J Natl Cancer Inst. 2023 Jul 12:djad137. doi: 10.1093.
    

    >> Share

    
    June 2023
20. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    

    >> Share

    
    
21. LI S, Nguyen-Dumont T, Southey MC, Hopper JL, et al
    RE: Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:757-759.
    

    >> Share

    
    May 2023
22. SHI J, Kraft P, Rosner BA, Benavente Y, et al
    Risk prediction models for endometrial cancer: development and validation in an international consortium.
    J Natl Cancer Inst. 2023;115:552-559.
    

    >> Share

    
    April 2023
23. GUPTA S, Hanna PE, Ouyang T, Yamada KS, et al
    Kidney Function in Patients with Ovarian Cancer Treated with Poly (ADP-ribose) polymerase (PARP) Inhibitors.
    J Natl Cancer Inst. 2023 Apr 19:djad070. doi: 10.1093.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share